An Open Label, Non-comparative, Multicenter Study to Assess the Pharmacokinetics, Safety and Efficacy of Tafenoquine (SB-252263, WR238605) in the Treatment of Pediatric Subjects With Plasmodium Vivax Malaria
Phase of Trial: Phase II
Latest Information Update: 11 Oct 2017
At a glance
- Drugs Tafenoquine (Primary) ; Chloroquine
- Indications Vivax malaria
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline
- 05 Oct 2017 Planned End Date changed from 29 May 2019 to 20 Feb 2019.
- 14 Sep 2017 Planned End Date changed from 22 Nov 2018 to 29 May 2019.
- 25 Apr 2017 Status changed from not yet recruiting to recruiting.